MIPS Changes for 2025

MIPS consists of 4 components   Quality Reporting, Promoting interoperability, Improvement Activities and Cost. Another way to participate in MIPS is through an MVP. When reporting traditional MIPS you can report on individual measure or you can report a MIPS Value Pathway (MVP).

Each year CMS updates the MIPS program.  This article will discuss the changes in the Quality Reporting portion of MIPS

Seven quality measures have been added

Ten quality measures have been removed

Sixty-Six measures have experienced substantial changes.

New Quality Measures

• #494: Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Clinician Level)
• #506 Positive PD-L1Biomarker Expression Test Result Prior to First Line Immune Checkpoint Inhibitor Therapy
• #507 Appropriate Germline Testing for Ovarian Cancer Patients
• #508 Adult COVID-19 Vaccination Status
• #509 Melanoma: Tracking and Evaluation of Recurrence
• #510 First-Year Standardized Waitlist Ratio
• #511 Percentage of Prevalent Patients Waitlisted and Percentage of Prevalent Patients Waitlisted in Active Status

Removed Quality Measures

• #104: Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High-Risk Prostate Cancer
• #137 Melanoma: Continuity of Care – Recall System: Oncology: Medical and Radiation – Plan of Care for Pain
• #254 Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain
• #260 Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)
• #409 Clinical Outcome Post Endovascular Stroke Treatment
• #433 Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair 
• #436: Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques
• #439 Age-Appropriate Screening Colonoscopy
• #452 Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies
• #472 Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture

On January 22, Registry Clearinghouse will host a free webinar to discuss the changes to the Quality Reporting portion of MIPS. 8 PM Eastern / 7 PM Central / 5 PM Pacific. Click here to register for the event